Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 6/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | CA12 | O43570 | 2/20 | 0.59 |
| ▸ | CA4 | P22748 | 2/20 | 0.59 |
| ▸ | CA6 | P23280 | 2/20 | 0.59 |
| ▸ | CA5A | P35218 | 2/20 | 0.59 |
| ▸ | CA7 | P43166 | 2/20 | 0.59 |
| ▸ | CA9 | Q16790 | 2/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.59 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.59 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.59 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | TTR | P02766 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5898485 | 1.00 | HCAR2 (0.74) | HCAR2LMNACA12CA4CA6 | |
| SCHEMBL5897900 | 1.00 | HCAR2 (0.74) | HCAR2LMNACA12CA4CA6 | |
| Ammonia Solution, Strong SCHEMBL27556861 | 0.98 | HCAR2 (0.72) | HCAR2LMNACA12CA4CA6 | |
| SCHEMBL28081360 | 0.92 | HCAR2 (0.63) | HCAR2LMNACA12CA4CA6 | |
| SCHEMBL357565 | 0.91 | HCAR2 (0.89) | HCAR2LMNACA12CA4CA6 | |
| SCHEMBL337503 | 0.91 | HCAR2 (0.89) | HCAR2LMNACA12CA4CA6 | |
| SCHEMBL337504 | 0.91 | HCAR2 (0.89) | HCAR2LMNACA12CA4CA6 | |
| SCHEMBL28388377 | 0.89 | LMNA (0.79) | HCAR2LMNACA12CA4CA6 | |
| SCHEMBL17695763 | 0.89 | HCAR2 (0.59) | HCAR2LMNACA12CA4CA6 | |
| SCHEMBL27659194 | 0.89 | HCAR2 (0.85) | HCAR2LMNACA12CA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12049444-B2 | Monomethyl fumarate precursor drug compounds and pharmaceutical compositions thereof | AGATHONBIO CO., LTD. (KR) | 2024-07-30 | — | — | US | claimed |
| US-12049444-B2 | Monomethyl fumarate precursor drug compounds and pharmaceutical compositions thereof | AGATHONBIO CO., LTD. (KR) | 2024-07-30 | — | — | US | disclosed |
| US-20210308922-A1 | METHOD FOR AUTOMATICALLY INJECTING MONOMER FOR OPTICAL MATERIAL INTO MOLD | KOC SOLUTION CO., LTD. (KR) | 2021-10-07 | — | — | US | disclosed |
| CN-109641878-B | DIPROVOCIM: effective TLR agonist | 斯克里普斯研究学院 | 2021-09-14 | — | — | CN | disclosed |
| EP-3875259-A1 | METHOD FOR AUTOMATICALLY INJECTING MONOMER FOR OPTICAL MATERIAL INTO MOLD | KOC Solution Co., Ltd. (KR) | 2021-09-08 | — | — | EP | disclosed |
| US-11040959-B2 | Diprovocims: a new and potent class of TLR agonists | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-06-22 | — | — | US | disclosed |
| EP-3445758-B1 | DIPROVOCIMS: A NEW AND POTENT CLASS OF TLR AGONISTS | SCRIPPS RESEARCH INST (US) | 2020-11-04 | — | — | EP | disclosed |
| US-20200207742-A1 | DIPROVOCIMS: A NEW AND POTENT CLASS OF TLR AGONISTS | THE SCRIPPS RESEARCH INSTITUTE | 2020-07-02 | — | — | US | disclosed |
| CN-109641878-A | DIPROVOCIM: a new class of effective TLR agonist | 斯克里普斯研究学院 | 2019-04-16 | — | — | CN | disclosed |
| US-7973041-B2 | Antiarthritic agents; psoriasis; anticancer agents;antiallergens; metalloprotease inhibitors. | INCYTE CORPORATION (US) | 2011-07-05 | — | — | US | disclosed |
| US-20090325889-A1 | HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | CAMPBELL DAVID ALAN | 2009-12-31 | — | — | US | disclosed |
| CN-101458341-A | Combination for stopping uv optical lens and capable of preventing aetiolation in heat treatment process and optical lens using same | SHIN DAE SPECIALTIES CO LTD (KR) | 2009-06-17 | — | — | CN | disclosed |
| US-7491724-B2 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION (US) | 2009-02-17 | — | — | US | disclosed |
| US-20080167288-A1 | Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases | LNCYTE CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
| US-6984648-B2 | Cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-01-10 | — | — | US | disclosed |
| US-20040162426-A1 | Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha | LU ZHONGHUI (US) | 2004-08-19 | — | — | US | disclosed |
| US-6743807-B2 | TREATMENT OF RHEUMATOID AND OSTEOARTHRITIS, CORNEAL, EPIDERMAL OR GASTRIC ULCERATION, TUMOR METASTASIS OR INVASION, PERIODONTAL DISEASE AND BONE DISEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-06-01 | — | — | US | disclosed |
| EP-1263755-A2 | CYCLIC BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-ALPHA | Bristol-Myers Squibb Pharma Company (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20020016336-A1 | Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-02-07 | — | — | US | disclosed |
| WO-2001070673-A2 | CYCLIC β-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-$g(a) | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016336-A1 | Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha | RNPEP, TNF, ANPEP | HCAR2 1090/4885LMNA 2122/4885CA12 573/4885 |
| US-20200207742-A1 | DIPROVOCIMS: A NEW AND POTENT CLASS OF TLR AGONISTS | TLR1, TLR4, TLR2 | HCAR2 228/4885LMNA 3718/4885CA12 4716/4885 |
| US-20090325889-A1 | HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | PREP, HPN, PRSS1 | HCAR2 2935/4885LMNA 2866/4885CA12 2989/4885 |
| US-20040162426-A1 | Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha | RNPEP, TNF, ANPEP | HCAR2 1090/4885LMNA 2122/4885CA12 573/4885 |
| US-11040959-B2 | Diprovocims: a new and potent class of TLR agonists | TLR1, TLR4, TLR2 | HCAR2 221/4885LMNA 3618/4885CA12 4745/4885 |
| US-20080167288-A1 | Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases | MMP25, MMP9, MMP24 | HCAR2 43/4885LMNA 970/4885CA12 299/4885 |
| US-12049444-B2 | Monomethyl fumarate precursor drug compounds and pharmaceutical compositions thereof | FH, FPGS, FAH | HCAR2 882/4885LMNA 4154/4885CA12 3452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.